(Q44701539)

English

Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin-paclitaxel for chemo-naïve non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002).

scientific article published on 11 September 2012

In more languages

default values for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin-paclitaxel for chemo-naïve non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002). (English)

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

phase III clinical trial

0 references

non-small-cell lung carcinoma

1 reference

based on heuristic

inferred from title

author name string

A Inoue

1

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

K Kobayashi

2

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

M Maemondo

3

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

S Sugawara

4

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

S Oizumi

5

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

H Isobe

6

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

A Gemma

7

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

M Harada

8

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

H Yoshizawa

9

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

I Kinoshita

10

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

Y Fujita

11

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

S Okinaga

12

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

H Hirano

13

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

K Yoshimori

14

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

T Harada

15

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

Y Saijo

16

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

K Hagiwara

17

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

S Morita

18

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

T Nukiwa

19

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

North-East Japan Study Group

20

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

11 September 2012

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

Annals of Oncology

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

24

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

54-59

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS214

21 January 2018

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS214

21 January 2018

Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS214

21 January 2018

A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS214

21 January 2018

Gefitinib for non-small-cell lung cancer patients with epidermal growth factor receptor gene mutations screened by peptide nucleic acid-locked nucleic acid PCR clamp

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS214

21 January 2018

Multicentre prospective phase II trial of gefitinib for advanced non-small cell lung cancer with epidermal growth factor receptor mutations: results of the West Japan Thoracic Oncology Group trial (WJTOG0403).

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS214

21 January 2018

Prospective phase II study of gefitinib in non-small cell lung cancer with epidermal growth factor receptor gene mutations

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS214

21 January 2018

Combined survival analysis of prospective clinical trials of gefitinib for non-small cell lung cancer with EGFR mutations.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS214

21 January 2018

Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS214

21 January 2018

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS214

21 January 2018

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS214

21 January 2018

Genetic heterogeneity of the epidermal growth factor receptor in non-small cell lung cancer cell lines revealed by a rapid and sensitive detection system, the peptide nucleic acid-locked nucleic acid PCR clamp

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS214

21 January 2018

Quality of life with gefitinib in patients with EGFR-mutated non-small cell lung cancer: quality of life analysis of North East Japan Study Group 002 Trial

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS214

21 January 2018

Screening for epidermal growth factor receptor mutations in lung cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS214

21 January 2018

Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS214

21 January 2018

Identifiers

10.1093/ANNONC/MDS214

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

release_fskpjygyfzcf3n5ow4bqdvmg5e

1 reference

https://api.fatcat.wiki/v0/release/fskpjygyfzcf3n5ow4bqdvmg5e

24 November 2022

based on heuristic

mapped directly with Wikidata item

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44701539&oldid=1838861675"